Crinetics breaks the commercial barrier with FDA nod for oral acromegaly med Palsonify
25th September 2025 Uncategorised 0The FDA on Thursday signed off on Crinetics’ paltusotine—now christened Palsonify—as a first-line treatment for certain adults with acromegaly. Unlike other somatostatin drugs that make up the bulk of current acromegaly care options, Palsonify is a small molecule, non-peptide therapy that can be taken orally, potentially freeing up patients from frequent and often painful injections.
More: Crinetics breaks the commercial barrier with FDA nod for oral acromegaly med Palsonify
Source: fierce